HEATR1 deficiency enhanced gastric cancer cell PANoptosis to boost anti-tumor immunity Authors: Ya Huang, Qingcheng Xu, Meijuan Zhu, Yawei Shen, Xianwen Zhang Published: 2026 ABSTRACT BackgroundDespite the promise of immune checkpoint inhibitors (ICIs) for gastric cancer (GC) treatment, limited cytotoxic T cell infiltration remains a major barrier to therapeutic efficacy. This study investigates whether targeting HEAT repeat containing 1 (HEATR1) can induce immunogenic PANoptosis to enhance anti-tumor immunity.MethodsBioinformatics analysis of TCGA-STAD cohort, syngeneic mouse models, and patient-derived organoids (PDOs) were employed to assess HEATR1 function. Mechanistic studies examined STAT1/IRF1 signaling, PANoptosis markers, and dendritic cell (DC) activation. Therapeutic efficacy was evaluated in combination with anti-PD1 immunotherapy.ResultsHEATR1 expression inversely correlated with CD8+ T cell infiltration in GC tissues and was associated with advanced tumor stage and lymph node metastasis. HEATR1 knockdown suppressed tumor growth in immunocompetent but not T cell-deficient mice, demonstrating immune-dependency. Mechanistically, HEATR1 deficiency stabilized STAT1 by inhibiting proteasome-mediated degradation, thereby sensitizing GC cells to IFN-γ-induced PANoptosis through STAT1/IRF1 signaling activation. This inflammatory cell death released damage-associated molecular patterns, which promoted DC maturation and cross-priming of CD8+ T cells. The resulting IFN-γ secretion established a positive feedback loop amplifying tumor cell PANoptosis. PDO models confirmed that HEATR1-silenced organoids exhibited enhanced PANoptosis and DC-mediated CD8+ T cell expansion. HEATR1 knockdown synergized with anti-PD1 therapy to significantly inhibit tumor progression.ConclusionsHEATR1 deficiency enhances GC cell sensitivity to IFN-γ-mediated PANoptosis via STAT1/IRF1 pathway activation, creating an immunogenic tumor microenvironment that potentiates ICI efficacy. These findings identify HEATR1 as a promising therapeutic target for improving GC immunotherapy outcomes.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1186/s10020-026-01574-6. Introduction Gastric cancer (GC) is one of the most common malignancies in the world, and current statistics show that GC is the fourth leading cause of cancer death worldwide, and the median survival rate for advanced patients is less than 12 months (Machlowska et al. 2020). The early symptoms of GC are difficult to diagnose, and most of the newly diagnosed patients with GC have reached the advanced stage. Currently, the main treatment methods for advanced GC patients include chemotherapy, radiotherapy, targeted therapy and immunotherapy (Joshi and Badgwell 2021). Although great progress has been made in the treatment of GC, the prognosis of most patients with GC is still not ideal. In recent years, the application of immune checkpoint inhibitor (ICI) therapy targeting programmed death-1 (PD-1) and programmed death ligand 1 (PD-L1) in the treatment of malignant tumors has made great breakthroughs (Rasihashemi et al. 2022, Li and Xu 2022). Recent studies have shown that the unique tumor immune microenvironment with insufficient infiltrating lymphocytes is a major reason for limiting the efficacy of cellular immunotherapy (Ding et al. 2019). One study examined samples from patients with various tumor types receiving ICIs and found that increased levels of CD8+ T cells in tumor tissue were positively correlated with efficacy (Kist et al. 2022). CD8+ T cells not only play a direct role in killing tumor cells, but also control tumor growth by releasing cytokines such as interferon-γ (IFN-γ) and tumor necrosis factor-α (Hoekstra et al. 2021). Moreover, the increase of CD8+ T infiltrating in subcutaneously transplanted GC tumors was found to contribute to the efficacy of PD-1 (He et al. 2017). Therefore, the increase of infiltrating lymphocytes in the tumor immune microenvironment is very important for the efficacy of ICIs. PANoptosis is defined as an inflammatory programmed cell death pathway, a type of PANoptosome formed by key molecules involved in apoptosis, necroptosis and pyroptosis. It regulates inflammatory cell death and host defense under the stimulation of damage-associated molecular patterns (DAMPs) or pathogen-associated molecular patterns (Kuriakose et al. 2016, Malireddi et al. 2019, Harkins et al. 2023). Notably, pyroptosis or necroptosis of cancer cells can induce potent anticancer immunity that can be treated in concert with ICIs, even for ICI-resistant tumors (Tang et al. 2020). Bioinformatics analysis revealed that the expression characteristics of PANoptosis can be used as a potential indicator to predict the survival rate and response to immunotherapy in patients with GC (Pan et al. 2022). However, there is no study on the influence of PANoptosis on immunotherapy of GC. HEAT repeat containing 1 (HEATR1) is a key molecule that regulates ribosome formation and influences the activity of proteasome in the cytoplasm. At present, abnormal expression of HEATR1 gene has been found in oral squamous cell carcinoma (Nakamura et al. 2021), non-small cell lung cancer (Ma et al. 2024), hepatocellular carcinoma (Yang et al. 2023), pancreatic cancer (Fang et al. 2020), and GC (Zhao et al. 2020). It was found that HEATR1 promoted the growth of GC cells, and apoptosis of GC cells was stimulated after HEATR1 knockdown (Zhao et al. 2020). This study will explore the molecular mechanism of HEATR1 influence on GC cell PANoptosis and whether HEATR1 promotes the killing ability of CD8+ T cells. In addition, patient-derived organoids (PDOs) are a new experimental model that can reproduce the disease characteristics of patients and cover as many disease phenotypes as possible (Yang et al. 2024). This study will apply this in vitro 3D model close to the physiological state to highlight the potential application value of HEATR1-mediated PANoptosis in clinical research and treatment. Materials and methods Bioinformatics analysis The transcriptome sequencing data of the Cancer Genome Atlas of Stomach Adenocarcinoma (TCGA-STAD) (Comprehensive 2014) patients (N = 373) and normal stomach samples (N = 32) were downloaded from Genotype-Tissue Expression (GTEx) (The 2020). And the analysis of differentially expressed genes associated with GC was performed using the DESeq2 package (Love et al. 2014). For the analysis of correlations of HEATR1 expression with clinical and pathological features of GC patients, 56 samples with incomplete clinical information were excluded, leaving a total of 317 samples (N = 317). The CIBERSORTx algorithm (Newman et al. 2019) was used to investigate the relationship of differentially expressed genes with immune cell infiltration abundance using TCGA data (Comprehensive 2014), and the correlations of HEATR1 with CD8+ T-cell abundance in GC tissues were analyzed. Clinical samples Fourteen patients with GC admitted to Northern Jiangsu People’s Hospital from January 2023 to December 2023 were selected as study subjects, and the surgically removed GC tissues were collected. The inclusion criteria were as follows: (1) age 18–80 years; (2) GC was diagnosed for the first time by gastroscopy and pathological examination; (3) all patients underwent radical resection of gastric carcinoma by laparoscopic surgery. (4) No radiotherapy, chemotherapy, or other anti-tumor treatment was administered prior to surgery. Peripheral blood from healthy donors and GC patients was collected from the Northern Jiangsu People’s Hospital, and peripheral blood mononuclear cells (PBMCs) were isolated by the density gradient centrifugation method. Peripheral blood samples were centrifuged at 300 g for 5 min, and after discarding the top plasma, the bottom blood was diluted to 30 mL with normal saline and transferred to a clean 50 mL centrifuge tube. Then, 15 mL of Ficoll lymphocyte separation medium (Cytiva) was added to the other 50 mL centrifuge tube, the 50 mL centrifuge tube containing blood was held in the left hand, and then the blood was slowly added to the surface of the lymphocyte separation medium. After both acceleration and deceleration were set to the lowest, the centrifuge tube was centrifuged at 2500 rpm for 25 min. After centrifugation, the buffy layers were aspirated, 10 mL of PBS was added and centrifuged at 2500 rpm for 25 min. The precipitate in the bottom layer was PBMCs. This study was approved by the Medical Ethics Committee of Northern Jiangsu People’s Hospital, and the patients and their families were informed, and the informed consent was signed by the patients themselves. Immunofluorescence staining Immunofluorescence staining was used to detect HEATR1, and CD8 levels in GC tissues (Chaplygina and Zhdanova 2024). GC tissue samples (thickness 0.3 cm) were prepared, fixed in 4% paraformaldehyde for 24 h at room temperature, dehydrated, and embedded in paraffin. Tissue sections were then subjected to antigen retrieval and blocking with 1% bovine serum albumin (Beijing Solarbio Technology Co. Ltd). Anti-HEATR1 (Santa Cruz Biotechnology, Dallas, TX, USA), or anti-CD8 (1:100, ab237709, Abcam) antibodies were then added and incubated overnight at 4℃. After three washes with PBS, fluorescent secondary antibodies were added and incubated for 1 h at room temperature in the absence of light. After three washes with PBS, the sections were sealed with DAPI (Sigma), and the staining was observed under a fluorescence microscope (Olympus). Cell lines and treatment Mouse GC cell line MFC (mouse fore-stomach carcinoma) were purchased from Wuhan Procell Biotechnology Co., Ltd., and were cultured in RPMI 1640 medium containing 10% fetal bovine serum (FBS, Hyclone) and 1% penicillin-streptomycin (Beyotime). Short hairpin RNA (shRNA) targeting mouse HEATR1 (sh-mHEATR1) (forward: 5’-CCGGTGCAGATAGTCTCATTGCTTGTCTCGAGACAAGCAATGAGACTATCTGCTTTTTG-3’; reverse: 5’-AATTCAAAAAGCAGATAGTCTCATTGCTTGTCTCGAGACAAGCAATGAGACTATCTGC-3’), sh-human HEATR1 (forward: 5’-CCGGTGCTGCAACATACATGATAATACTCGAGTATTATCATGTATGTTGCAGC-3’; reverse: 5’-AATTCAAAAAGCTGCAACATACATGATAATACTCGAGTATTATCATGTATGTTGCAGC-3’), or sh-NC (forward: 5’-CCGGTCCTAAGGTTAAGTCGCCCTCGCTCGAGCGAGGGCGACTTAACCTTAGGTTTTTG-3’; reverse: 5’-AATTCAAAAACCTAAGGTTAAGTCGCCCTCGCTCGAGCGAGGGCGACTTAACCTTAGG-3’) was inserted into pLKO.1 vector. pLKO.1-sh-NC, pLKO.1-sh-hHEATR1, pLKO.1-sh-mHEATR1 was used as the transfer plasmid, and then co-transfected into 293 T cells with the lentiviral packaging vector (psPAX2) and envelope vector (pMD2.G) according to the instructions of Lipofectamine™ 3000 (ThermoFisher). After the lentiviral vectors (LV) were successfully constructed, LV-sh-NC, LV-sh-mHEATR1 were used to infect MFC cells. Stably transfected MFC cells were obtained by screening with 2 µg/mL puromycin for 2 weeks. Human GC cell lines MKN45 and HGC-27 were purchased from Wuhan Procell Biotechnology Co., Ltd., and were cultured in RPMI 1640 medium containing 10% FBS and 1% penicillin-streptomycin. MKN-45 and HGC-27 cells were transfected with si-HEATR1 (5’-GCTGCAACATACATGATAATA-3’) or si-NC (5’-CCTAAGGTTAAGTCGCCCTCG-3’) by Lipofectamine™ 3000 (ThermoFisher) and treated with IFN-γ (10 ng/mL) for 24 h, and grouped into control, si-HEATR1, IFN-γ, IFN-γ + si-HEATR1. MKN-45 cells were treated with IFN-γ, si-interferon regulatory factor 1 (IRF1, 5’-GGCTAGAGATGCAGATTAATT-3’) + si-HEATR1, and grouped into IFN-γ, IFN-γ + si-IRF1, IFN-γ + si-HEATR1, IFN-γ + si-HEATR1 + si-IRF1. MKN-45 cells were treated with si-HEATR1 and Z-VAD-FMK (VAD, 25 µM)/necrostatin-1 (Nec, 20 µM)/Ac-DMPD (DMPD, 20 µM), and grouped into si-HEATR1, si-HEATR1 + VAD, si-HEATR1 + Nec, and si-HEATR1 + DMPD. MKN-45 cells were treated with IFN-γ, si-HEATR1 and/or fludarabine, and grouped into IFN-γ, IFN-γ + si-HEATR1, IFN-γ + si-HEATR1 + fludarabine. To collect the supernatant of MKN-45 to remove the interference of IFN-γ, VAD, Nec, DMPD, etc., the above drugs were treated for 24 h and then replaced by fresh serum-free medium and continued to incubate for 24 h, then the supernatant was collected for the subsequent experiments. Tumor cell supernatant challenged DCs co-cultured with CD8+ T cells Cultivation of DCs: After culturing human PBMC in RPMI-1640 containing 10% FBS and 1% penicillin-streptomycin for 5 h, the suspended cells were discarded and the remaining adherent cells were cultured in RPMI-1640 containing interleukin-4 (IL-4, PeproTech) and granulocyte-macrophage colony-stimulating factor (GM-CSF, PeproTech) at 100 ng/mL each, which was recorded as day 0. On day 2 and day 4, half of the medium was replaced and the cytokines IL-4 and GM-CSF were added. The immature DCs were collected on day 5 for the following study. Generation of tumor cell supernatant challenged DCs: DCs were co-cultured with 100 µL/mL MKN-45 cell supernatant treated with si-HEATR1, IFN-γ and Z-VAD-FMK/necrostatin-1/Ac-DMPD for 24 h, and then washed twice in serum-free RPMI 1640 medium. DCs were grouped into si-HEATR1 + IFN-γ, si-HEATR1 + IFN-γ + VAD, si-HEATR1 + IFN-γ + Nec, si-HEATR1 + IFN-γ + DMPD. Isolation of CD8+ T cells: CD8+ T cells in PBMC were isolated using the EasySep immunomagnetic bead sorting system (STEMCELL Technologies). The enrichment cocktail of 50 µL/mL was added to the suspended PBMC (2.5 × 107/mL) and incubated for 10 min at room temperature. Then 150 µL/mL magnetic particles were added, mixed and incubated for 10 min at room temperature. The enrichment cocktail and magnetic particle mixture were diluted by adding EasySep Buffer according to the kit instructions, mixed well and incubated on an EasySep Magnet. The cell suspension was transferred to a new tube and centrifuged at 300 g for 5 min to isolate CD8+ T cells. Co-culture of DCs and CD8+ T cells: The concentration of T cells obtained was 5 × 109/L after adjustment with serum-free 1640 medium. CD8+ T cells were incubated with tumor cell supernatant pulsed DCs at a responder-to-stimulator ratio of 10:1. After 5 days of culture, flow cytometric analysis was performed. Establishment of murine gastric tumor model Female 615 mice or BALB/c nude mice (4–6 weeks) were subcutaneously inoculated with sh-HEATR1-transfected MFC cells (0.2 mL, 2.5 × 107 cells/mL), and mice receiving negative shRNA-transfected MFC cells were used as controls. After 5 days, sh-HEATR1 group 615 mice were treated with αPD-1 or anti-mouse CD11c mAb. For αPD-1 treatment, tumor-bearing mice received 200 µg αPD-1 (ThermoFisher) intraperitoneally every 3 days. For depletion of CD11c+ DCs and CD8+ T, tumor-bearing mice were injected intraperitoneally with 200 µg anti-mouse CD11c mAb (Biolegend) and anti-mouse CD8α (Bio X Cell) at 400 µg per mouse respectively on days 5, 8, 11, and 14, 17 d after tumor cell inoculation. At 20 days after the last administration, the subcutaneous tumor was completely removed from the euthanized mice, weighed, and recorded. Flow cytometry was used to detect CD11c+ cells in lymph nodes, spleen and tumors to confirm depletion efficiency. The implanted tumor tissues were completely dissected, and 1 mL collagenase (Biosharp) was added for digestion at 37℃ for 1 h. The digestion was terminated by adding 1 mL 2% FBS. After sieving through a 200-mesh cell filter, the cell suspension was transferred to a 15-mL centrifuge tube, 1 mL precooled PBS was added, and centrifuged at 4℃ and 1500 rpm/min for 5 min. The single cell suspension was obtained by adding PBS after discarding the supernatant. The animal experimental study was approved by the Northern Jiangsu People’s Hospital. Sorting and expansion of CD8+ tumor infiltrating lymphocyte (TIL) subsets Cells derived from enzymatically digested solid tumors of sh-HEATR1 MFC tumor-bearing mice were cultured overnight in complete medium [RPMI-1640-Glutamax supplemented with 10% heat-inactivated fetal bovine serum (FBS), 100 U/mL penicillin, and 100 µg/mL streptomycin]. CD8+ T cells were subsequently isolated using the Mouse CD8+ T Cell Isolation Kit (StemCell Technologies) and activated with Dynabeads™ Mouse T-Activator CD3/CD28 for T-Cell Expansion and Activation (ThermoFisher Scientific) according to the manufacturer’s instructions. MFC reactivity assay For direct contact assays, freshly isolated and expanded CD8+ T cells were rested overnight in medium without interleukin-2 (IL-2) to serve as effector cells. Tumor specificity was assessed by coculturing effector cells with relevant tumor cell lines (target cells) or unrelated tumor cells. Briefly, 96-well plates were pre-coated with anti-CD28 antibody to provide the second signal. Effector and target cells were plated at effector-to-target (E: T) ratios of 0.5:1, 1:1, 5:1, and 10:1. Following 12 h of direct coculture, lactate dehydrogenase (LDH) release was measured using an LDH cytotoxicity assay kit (Beyotime) according to the manufacturer’s protocol. CD8+ T cell degranulation was evaluated by flow cytometric analysis of CD107a surface expression. For indirect contact assays, freshly isolated and expanded CD8+ T cells (1 × 10⁴) were seeded into the upper chamber of Transwell plates containing 6.5 mm cell culture inserts with 0.4 μm pore polyester membranes (CLS3379, Corning). MFC cells (1 × 10⁴) were plated in the lower chamber. After 12 h of coculture, LDH release in the lower chamber was measured, and IFN-γ levels in the lower chamber were quantified by ELISA. Intracellular IFN-γ expression in CD8+ T cells from the upper chamber was analyzed by flow cytometry. Flow cytometry The percentage of CD3+CD8+ cells in the single cell suspension of subcutaneously transplanted tumor tissues and IFN-γ expression on CD8+Ki67+ cells were detected by flow cytometry analysis. The percentage of HLA-DR and CD86 positive cells in DCs, CD8+Ki67+ cells in CD3 positive cells, HLA-DR+CD80+ cells in CD11c+ cells were detected by flow cytometry analysis. Cells were labeled with appropriate fluorescent antibodies [APC anti-mouse CD3 antibody (Biolegend, 100235); PE anti-mouse CD8a antibody (Biolegend, 100707); FITC rat anti-mouse IFN-γ (BD bioscience, 554411); APC mouse anti-human CD86 (BD bioscience, 571636); APC mouse anti-human HLA-DR (BD bioscience, 560744); PE hamster anti-mouse CD11c (BD bioscience, 557401); FITC rat anti-mouse CD86 (BD bioscience, 553691); APC CD80 (B7-1) monoclonal antibody (eBioscience, 17–0801-82); FITC mouse anti-human CD8 (BD Bioscience, 561947); rabbit monoclonal anti-Ki67 (ab16667, Abcam) + goat anti-rabbit IgG Alexa Fluor™ 647 (Invitrogen, A-21245)] and detected by flow cytometry (BD Biosciences). The results were analyzed using FlowJo software. Adoptive CD8+ T cell transfer experiment MFC tumor-bearing mice received cyclophosphamide (Cytoxan, CTX) at 100 mg/kg via intravenous injection on day 7 post-tumor inoculation. On day 8, mice were intravenously infused with 1 × 10⁷ CD8+ T cells per mouse. All transferred CD8+ T cells were expanded in vitro to day 6 prior to administration. Subsequently, recombinant IL-2 was administered systemically at a dose of 2 × 10⁴ IU per injection, twice daily (every 12 h) for 2 consecutive days. Anti-mouse IFN-γ antibody (200 µg per mouse, Bio X Cell) was given on days 11, 14, and 17. Mice were euthanized on day 20 for subsequent analysis. Western blot assay The protein expressions of mixed line kinase region-like protein (MLKL), p-MLKL, gasdermin E (GSDME), c-GSDME, caspase3, c-caspase3, signal transducer and activator of transcription-1 (STAT1), p-STAT1, IRF1, IFN-γ, and HEATR1 in the subcutaneously transplanted tumor tissues or MKN-45 cells were detected by Western blot assay. Total protein was extracted from the cell lysate, and the protein concentration was quantified by BCA kit (Beyotime). After preparation of 10% SDS-PAGE gel, sample loading, electrophoresis, electrotransfer and sealing were performed. Primary antibodies were added and incubated overnight at 4℃, and secondary antibodies were added and incubated at room temperature for 1 h. Finally, ECL kit (Biosharp) was used to visualize protein bands. Detection of cell death Cell death of MKN-45 cells was detected by co-staining with YO-PRO-1 (YP1) and propidium iodide (PI). MKN-45 cells at the logarithmic growth stage were inoculated into 96-well plates at a density of 1 × 104 cells per well. After adhesion, the cells were treated with IFN-γ and/or si-HEATR1. According to the instructions of the Apoptosis and Necrosis Detection Kit with YO-PRO-1 and PI (Beyotime), 100 µL detection buffer, 0.1 µL YP1, 0.1 µL PI were added to each well and incubated under 5% CO2 at 37℃ for 10 min in the dark. Cell staining was observed under a fluorescence microscope (Echo Laboratories) and statistically analyzed. The YP1-positive cell (green) indicates that the cell underwent apoptosis or necroptosis. The PI-positive cell (red) indicates that the cell underwent apoptosis, necroptosis, pyroptosis, or ferroptosis. Early and late apoptosis of MKN-45 cells was detected by Annexin V FITC/PI flow cytometry assay. After digestion, IFN-γ and/or si-HEATR1 treated MKN-45 cells were suspended in cold PBS and counted. The cell concentration was adjusted to 1 × 106/mL, 100 µL cell suspensions were taken into the flow-through tube, 5 µL FITC-labeled Annexin V and 5 µL PI staining solution were added, and incubated at room temperature for 15 min. Then 400 µL binding buffer was added and mixed, and apoptosis was detected by flow cytometry, and the early (Annexin V+/PI−) and late (Annexin V+/PI+) apoptosis rates were statistically analyzed. Enzyme-linked immunosorbent assay (ELISA) assay HMGB1 and HSP70 levels in MKN-45, HGC-27 cells or PDOs were detected by ELISA assay. The cell medium was collected, centrifuged at 300 g for 5 min at room temperature, and the supernatant was transferred to a new EP tube for sample use. According to the instructions of HMGB1 ELISA kit (Beyotime) and HSP70 ELISA kit (Sigma), the standard product was configured with gradient concentration, and the standard product and samples were added to the coated well plate, and incubation and color development were performed according to the instructions. The absorbance of each well was measured at 450 nm using an enzyme analyzer (ThermoFisher). According to the absorbance results of the gradient concentration standard, the standard curve was drawn to calculate the protein concentration of each sample. Protein stability test and treatment with proteasome inhibitor MG132 When MKN-45 cells reached approximately 60% confluence, cell transfection of si-HEATR1 or si-NC was performed. After 30 h, 30 µg/mL cycloheximide (CHX, MedChemExpress) was added. Cells were digested with trypsin at 0, 1, 2, and 3 h after the addition of CHX, and Western blot analysis was performed. After 30 h of cell transfection, 10 µM MG132 (MedChemExpress) was added and cultured for 3 h, followed by Western blot analysis. Proteasome activity assay Proteasome activity was measured using the Proteasome-Glo™ Assay System (Promega) according to the manufacturer’s instructions. At 48 h post-siRNA transfection, 26 S proteasome chymotrypsin-like, trypsin-like, and caspase-like activities were detected using the Promega Proteasome-Glo™ system. All experiments were performed in triplicate. Relative proteasome activity was calculated based on blank-corrected relative light units (RLU) for statistical analysis. Quantitative reverse transcription-polymerase chain reaction (RT-PCR) IRF1 mRNA levels in subcutaneously transplanted tumor tissues or MKN-45 cells were determined by quantitative RT-PCR. Total RNA was extracted from intervention cells using TRIzol reagent (Invitrogen). Then, the concentration and purity of total RNA were determined by spectrophotometer (DeNovix DS-11), cDNA was synthesized by reverse transcription, and then quantitative RT-PCR reaction was performed using cDNA as template. β-Actin was used as an internal control, and the relative mRNA expression levels of the target genes were calculated using the 2−△△Ct method. The primer sequence is as follows: human IRF1: forward: 5’-ACACAGGCCGATACAAAGCA-3’; reversed: 5’-TATCAGGGCTGGAATCCCCA-3’; human β-actin: forward: 5’-CACTCTTCCAGCCTTCCTTC-3’; reversed: 5’-GTACAGGTCTTTGCGGATGT-3’; mouse IRF1: forward: 5’-GCAAACTTCCGTTGTGCCAT-3’; reversed: 5’-TCGGCTGGACTTGGACTTTC-3’; mouse β-actin: forward: 5’-CAGCCTTCCTTCTTGGGTATG-3’; reversed: 5’- GGCATAGAGGTCTTTACGGATG-3’. Establishment of GC PDOs The harvested GC tissue was cut into small pieces with sterile scissors, rinsed with PBS for 2 min, and then a small piece of tissue with better activity was selected for modeling GC organoids. The GC tissues were quickly cut into pieces in the digestion solution, then transferred to a 50 mL centrifuge tube, placed in a 37℃ shaker, shaken at 200 rpm, and observed every 5 min. The tissue was lysed into individual cells by rapid aspiration with a pipetting gun. The cell suspension that completed the lysis was filtered through a 100 μm cell sieve. The filtered 15 mL centrifuge tube containing the cell suspension was centrifuged at 300 g for 5 min. The cell suspension was mixed with pre-melted Matrigel (Corning) (30:70 vol/vol), and then 1500 cells/30 µL per well were inoculated into a 24-well plate to form droplet-like protrusions. The plates were placed in an incubator at 37 °C for 10 min, and 500 µL of Gastric Cancer Organoid Complete Medium (GCOM-100, SHR Biotechnology, Wuxi, Jiangsu, China) was added and cultured in a 5% CO2 incubator at 37 °C. Cell exchange was performed every 2–3 days, and 200 µL of medium was aspirated and 300 µL of fresh GC organoid complete medium was added. Follow-up experiments were performed after 21 days of expansion. Lentiviral transduction of PDOs According to the above methods, LV-sh-NC and LV-sh-HEATR1 were constructed and used to infect GC organoids. The organoids in healthy growth state were washed with PBS on ice, then 1 mL TrypLE (Invitrogen) was added and placed at 37℃ for organoid digestion. Digestion was stopped after the organoids formed a single cell suspension and centrifuged at 300 g and 4℃ for 5 min. After discarding the supernatant, 1 × 104 cell suspension containing lentivirus (LV) infection system [LV-sh-HEATR1 (multiplicity of infection = 50) was thoroughly mixed with complete medium (1:1) and 8 µmol/mL polybrene (Sigma) in a 24-well plate. The mixture was then transferred to a non-tissue culture treated plate and centrifuged at 300 g for 1 h. The supernatant was removed, an appropriate amount of Matrigel was added to re-precipitate the cells, and the mixture was allowed to solidify. After 30 min, organoid complete medium was added and the culture was continued for 72 h. Finally, 2 µg/mL puromycin was used to screen for lentivirus-positive organoids for two weeks. A follow-up experiment was performed after 24 h of IFN-γ treatment alone. PDO supernatant challenged DCs cocultured with CD8+ T cells Human PBMC-derived DCs were collected as described above and then co-cultured with autologous PDO supernatant (collection method same as MKN-45) for training, and DC maturation was confirmed by FCM. The autologous CD8+ T cells were incubated with the pulsed DCs at a responder-to-stimulator ratio of 10:1. After 5 days of culture, the proliferation fraction of CD8+ T cells in the suspension cells was identified by Ki67+CD8+. Co-culture system of PDOs and CD8+ T cells Early and late apoptosis of PDOs was detected by Annexin V FITC/PI flow cytometry assay. The resulting CD8+ T cells, which responded to antigen cross-presenting DCs pre-matured by organoid supernatant, were cocultured with PDO single cells at a ratio of 1:5 (T: E) for 24 h in the combined medium (half GC organoid culture medium + half T cell culture medium). Cells were then harvested for Annexin V-PI analysis. Statistical analysis The correlations of HEATR1 expression with clinical and pathologic features of GC patients were analyzed by chi-squared test. The correlations of HEATR1 with the abundance of CD8+ T cells in GC tissues were analyzed by Spearman correlation analysis. SPSS 25.0 statistical software was used for statistical analysis, and data were expressed as mean ± SD. Unpaired t-test was used to compare the results between the two groups. One-way or two-way ANOVA with Tukey’s post-hoc was used to compare the results among multiple groups. P < 0.05 was considered statistically significant. Results HEATR1 knockdown inhibits GC growth and depends on cytotoxic T cell response HEATR1 was markedly overexpressed in GC tissues according to the TCGA database (Figure S1A) and was significantly correlated with regional lymph node metastasis (N) (P = 0.0070) and GC stage (P = 0.029) (Table S1), suggesting that HEATR1 might promote GC progression. Further bioinformatics analysis of the TCGA dataset revealed that HEATR1 expression was inversely associated with CD8+ T cell infiltration in tumor tissue (Fig. 1A). We performed HEATR1 IHC on 14 GC specimens, and the clinical characteristics of all patient samples were summarized in Table S2. The stained sections were independently reviewed and scored based on staining intensity as follows: 0 (negative), 1 (weak), 2 (moderate), and 3 (strong) (Lin et al. 2022). The total IHC score was calculated by multiplying the intensity score by the percentage of positively stained cells (Figure S1B). Subsequently, the 14 samples were stratified into high- and low-expression groups based on the median IHC score, followed by HEATR1 and CD8 immunofluorescence staining and semi-quantitative analysis (Fig. 1B), indicating that HEATR1 may be involved in cytotoxic T cell responses. To clarify the effect of HEATR1 on GC tumor growth, we established stable HEATR1-knockdown MFC cell lines (Figure S1C-D) and subcutaneously inoculated them into 615 mice and T cell-deficient BALB/c nude mice. Although the fourth tumor in the sh-HEATR1 group exhibited a slightly larger size than that in the sh-NC group (Fig. 1C), this single outlier does not alter the overall conclusion that MFC syngeneic tumors in wild-type 615 mice (with an intact immune system) displayed reduced tumor growth following HEATR1 knockdown, whereas no significant changes were observed in nude mice (Fig. 1C-D), indicating that the anti-tumor effect of HEATR1 knockdown is dependent on the immune microenvironment. Notably, CD8+ T cell infiltration in syngeneic tumors was increased in the HEATR1 knockdown group in 615 mice (Fig. 1E). Furthermore, after blocking CD8+ T cell activity with anti-CD8 antibody, the tumor growth delay mediated by HEATR1 knockdown was significantly attenuated (Fig. 1F), suggesting that low HEATR1-expressing gastric tumor cells delay tumor progression in a manner dependent on cytotoxic T cell responses. Fig. 1HEATR1 expression in GC tissues and its association with CD8+ T cell-mediated anti-tumor immunity. A Spearman correlation analysis between HEATR1 expression and CD8+ T cell infiltration in GC tissues from the TCGA database. B Representative immunofluorescence staining of HEATR1 (green), and CD8 (red) in clinical GC tissue samples. Nuclei were counterstained with DAPI (blue). Scale bar = 20 μm. For clinical sample stratification, immunohistochemical staining of HEATR1 was performed on 14 GC specimens, and the median expression value was used as the threshold to define high (above) and low (below) HEATR1 expression groups. C-D Tumor growth curves of MFC syngeneic tumors in immunocompetent 615 mice (C) and T cell-deficient BALB/c nude mice (D) following subcutaneous inoculation of HEATR1-knockdown or control MFC cells (n = 5 per group). Tumor size was measured at indicated time points. Scale Bar = 10 mm. E Flow cytometric quantification of CD3+CD8+ T cell infiltration (left panel) and intracellular IFN-γ expression in CD3+CD8+ T cells (right panel) in syngeneic tumors from 615 mice. Five mice per group were euthanized, and their tumor tissues were enzymatically digested into single-cell suspensions for subsequent flow cytometric analysis. F Tumor growth curves showing restored tumorigenic capacity of HEATR1-knockdown MFC cells following CD8+ T cell depletion with anti-CD8 antibody in 615 mice (n = 5 per group). Data are presented as mean ± SD. Statistical significance was determined by unpaired two-tailed Student’s t-test. **P < 0.01 versus sh-NC control HEATR1 expression in GC tissues and its association with CD8+ T cell-mediated anti-tumor immunity. A Spearman correlation analysis between HEATR1 expression and CD8+ T cell infiltration in GC tissues from the TCGA database. B Representative immunofluorescence staining of HEATR1 (green), and CD8 (red) in clinical GC tissue samples. Nuclei were counterstained with DAPI (blue). Scale bar = 20 μm. For clinical sample stratification, immunohistochemical staining of HEATR1 was performed on 14 GC specimens, and the median expression value was used as the threshold to define high (above) and low (below) HEATR1 expression groups. C-D Tumor growth curves of MFC syngeneic tumors in immunocompetent 615 mice (C) and T cell-deficient BALB/c nude mice (D) following subcutaneous inoculation of HEATR1-knockdown or control MFC cells (n = 5 per group). Tumor size was measured at indicated time points. Scale Bar = 10 mm. E Flow cytometric quantification of CD3+CD8+ T cell infiltration (left panel) and intracellular IFN-γ expression in CD3+CD8+ T cells (right panel) in syngeneic tumors from 615 mice. Five mice per group were euthanized, and their tumor tissues were enzymatically digested into single-cell suspensions for subsequent flow cytometric analysis. F Tumor growth curves showing restored tumorigenic capacity of HEATR1-knockdown MFC cells following CD8+ T cell depletion with anti-CD8 antibody in 615 mice (n = 5 per group). Data are presented as mean ± SD. Statistical significance was determined by unpaired two-tailed Student’s t-test. **P < 0.01 versus sh-NC control HEATR1-knockdown GC cells exhibit enhanced sensitivity to IFN-γ-mediated paracrine stimulation by CD8+ T cells TILs are naturally occurring T cells capable of recognizing tumor-associated antigens (Ags), including neo-Ags. To evaluate the cytotoxic capacity of tumor-infiltrating CD8+ T cells against HEATR1-knockdown GC cells, we performed direct coculture assays using CD8+ T cells isolated and expanded from sh-HEATR1 MFC syngeneic tumors with MFC target cells at E: T ratios of 0.5:1, 1:1, 5:1, and 10:1. Notably, CD8+ T cells demonstrated significantly enhanced cytotoxicity against sh-HEATR1 MFC cells at low E: T ratios of 0.5:1 and 1:1 (Fig. 2A-B). However, no significant difference in CD107a surface expression was observed between the two groups (Fig. 2C), indicating comparable degranulation and target cell recognition capacity of CD8+ T cells. Given that CD8+ T cells eliminate target cells through either direct contact or indirect paracrine mechanisms, we hypothesized that the more severe damage observed in the sh-HEATR1 group might be attributed to the paracrine pathway. Consistent with this hypothesis, Transwell experiments revealed markedly elevated LDH release from sh-HEATR1 MFC cells in the lower chamber (Fig. 2D-E), demonstrating that HEATR1-knockdown GC cells are more susceptible to CD8+ T cell-mediated paracrine cytotoxicity. Fig. 2HEATR1 deficiency enhances GC cell sensitivity to CD8+ T cell-derived IFN-γ-mediated cytotoxicity. A-B Lactate dehydrogenase (LDH) release assay showing cytotoxicity of CD8+ T cells isolated from sh-HEATR1 MFC syngeneic tumors against MFC target cells at indicated effector-to-target (E: T) ratios (n = 3 biological replicates per group). C Flow cytometric analysis of CD107a surface expression on CD8+ T cells following direct coculture with MFC cells (n = 3). D-E LDH release in the lower chamber of Transwell plates following indirect coculture of CD8+ T cells with MFC cells (n = 3). F-G Intracellular IFN-γ expression in CD8+ T cells from the upper chamber (F) and IFN-γ levels in the lower chamber (G) measured by flow cytometry and ELISA, respectively (n = 3). H-I LDH release assays showing the effect of anti-IFN-γ antibody blockade on CD8+ T cell-mediated cytotoxicity against MFC cells under direct (H) and indirect (I) coculture conditions (n = 3). J Tumor growth curves of MFC syngeneic tumors in 615 mice following adoptive transfer of CD8+ T cells with or without anti-IFN-γ antibody treatment (n = 5 mice per group). Data are presented as mean ± SEM. Statistical significance was determined by two-way ANOVA with Bonferroni post-hoc test (B, J) or unpaired two-tailed Student’s t-test (C-I). *P < 0.05, **P < 0.01, #P < 0.05, ##P < 0.01, ns = not significant HEATR1 deficiency enhances GC cell sensitivity to CD8+ T cell-derived IFN-γ-mediated cytotoxicity. A-B Lactate dehydrogenase (LDH) release assay showing cytotoxicity of CD8+ T cells isolated from sh-HEATR1 MFC syngeneic tumors against MFC target cells at indicated effector-to-target (E: T) ratios (n = 3 biological replicates per group). C Flow cytometric analysis of CD107a surface expression on CD8+ T cells following direct coculture with MFC cells (n = 3). D-E LDH release in the lower chamber of Transwell plates following indirect coculture of CD8+ T cells with MFC cells (n = 3). F-G Intracellular IFN-γ expression in CD8+ T cells from the upper chamber (F) and IFN-γ levels in the lower chamber (G) measured by flow cytometry and ELISA, respectively (n = 3). H-I LDH release assays showing the effect of anti-IFN-γ antibody blockade on CD8+ T cell-mediated cytotoxicity against MFC cells under direct (H) and indirect (I) coculture conditions (n = 3). J Tumor growth curves of MFC syngeneic tumors in 615 mice following adoptive transfer of CD8+ T cells with or without anti-IFN-γ antibody treatment (n = 5 mice per group). Data are presented as mean ± SEM. Statistical significance was determined by two-way ANOVA with Bonferroni post-hoc test (B, J) or unpaired two-tailed Student’s t-test (C-I). *P < 0.05, **P < 0.01, #P < 0.05, ##P < 0.01, ns = not significant Effector CD8+ T cells are potent cytotoxic cells that produce IFN-γ, which can inhibit tumor proliferation and angiogenesis. We observed robust IFN-γ expression in CD8+ T cells in the upper chamber (Fig. 2F), with detectable levels in the lower chamber (Fig. 2G). Importantly, blockade of IFN-γ signaling using anti-IFN-γ antibody in the lower chamber attenuated the heightened vulnerability of HEATR1-knockdown cells to CD8+ T cell-mediated cytotoxicity under both direct and indirect coculture conditions (Fig. 2H-I). Furthermore, IFN-γ expression was significantly elevated in syngeneic tumors derived from HEATR1-knockdown MFC cells in 615 mice (Figure S2A). To determine whether intra-tumoral IFN-γ contributes to immune microenvironment-mediated tumor cell regulation, we collected tumor tissue supernatants from HEATR1-knockdown 615 mice and treated MFC cells with or without anti-IFN-γ antibody. The results demonstrated that tumor supernatants from 615 mice exacerbated the reduced viability of HEATR1-knockdown MFC cells, whereas anti-IFN-γ treatment restored cell viability in this group (Figure S2B). To directly elucidate the regulatory effect of CD8+ T cell-derived IFN-γ on HEATR1-knockdown MFC cells, we performed adoptive transfer of TIL-derived CD8+ T cells into MFC tumor-bearing mice. sh-HEATR1 MFC tumor-bearing mice exhibited enhanced sensitivity to CD8+ T cell adoptive transfer compared to sh-NC controls. However, administration of anti-IFN-γ antibody on day 3 post-transfer rapidly diminished the therapeutic efficacy of CD8+ T cells in sh-HEATR1 tumor-bearing mice (Fig. 2J). Collectively, these data indicate that intra-tumoral IFN-γ derived from CD8+ T cells further exacerbates the death of HEATR1 low-expressing tumor cells, both in vitro and in vivo. HEATR1 knockdown aggravates GC cell PANoptosis initiated by IFN-γ To further determine the effect of HEATR1 knockdown on GC cells, MKN-45 cells with low HEATR1 expression were subjected to IFN-γ treatment. siRNA-mediated HEATR1 knockdown alone failed to induce late apoptosis/necroptosis (AnnV+PI+ cells), with only a slight increase in early apoptosis (AnnV+PI− cells) (Fig. 3A). However, under IFN-γ stimulation, both late apoptosis/necroptosis and early apoptosis were significantly increased in the HEATR1 knockdown group (Fig. 3A). These results indicated that HEATR1 knockdown alone could not induce GC cell death, but under IFN-γ stimulation, it could trigger multiple modes of GC cell death. To further investigate the specific types of GC cell death, YP1/PI staining was performed, and the results showed that HEATR1 knockdown significantly enhanced IFN-γ-stimulated cell death, including apoptosis/necroptosis (YP1+ cells) and necroptosis, pyroptosis, or ferroptosis (PI+ cells) (Fig. 3B). These findings suggested that HEATR1 knockdown combined with IFN-γ treatment could stimulate PANoptosis in GC cells. Consistently, HEATR1 knockdown increased the IFN-γ-induced expression of PANoptosis markers (p-MLKL, c-GSDME, and c-caspase3) in MKN-45 cells (Fig. 3C). Notably, the expression levels of these proteins induced by the co-treatment of IFN-γ and HEATR1 knockdown were higher than those induced by IFN-γ alone. Fig. 3HEATR1 knockdown aggravates IFN-γ-initiated PANoptosis in GC cells. A Flow cytometric analysis of early apoptosis (Annexin V⁺/PI⁻) and late apoptosis/necroptosis (Annexin V⁺/PI⁺) in MKN-45 cells transfected with si-HEATR1 and/or treated with IFN-γ. *P < 0.05, **P < 0.01 vs. si-NC; #P < 0.05, ##P < 0.01 vs. IFN-γ alone. B Representative fluorescence images and quantification of YP1/PI staining in MKN-45 cells. YP1⁺ cells (green) indicate apoptosis/necroptosis; PI⁺ cells (red) indicate necroptosis, pyroptosis, or ferroptosis. Scale bar = 50 μm. **P < 0.01 versus si-NC; ##P < 0.01 versus IFN-γ alone. C Western blot analysis of PANoptosis markers (p-MLKL, c-GSDME, c-caspase3) and HEATR1 in MKN-45 cells. D Bright field (BF) and HE staining of patient-derived organoids (PDOs) and tumor tissues with HEATR1 high and low expressions. E Immunofluorescence staining against HEATR1 of PDOs and tumor tissues. F Western blot analysis of PANoptosis markers in PDOs with high versus low HEATR1 expression following IFN-γ treatment. G Western blot analysis of PANoptosis markers in tumor tissues from the CD8⁺ T cell adoptive transfer sh-HEATR1 MFC model, with or without anti-IFN-γ antibody treatment. Data represent mean ± SD. N = 3 HEATR1 knockdown aggravates IFN-γ-initiated PANoptosis in GC cells. A Flow cytometric analysis of early apoptosis (Annexin V⁺/PI⁻) and late apoptosis/necroptosis (Annexin V⁺/PI⁺) in MKN-45 cells transfected with si-HEATR1 and/or treated with IFN-γ. *P < 0.05, **P < 0.01 vs. si-NC; #P < 0.05, ##P < 0.01 vs. IFN-γ alone. B Representative fluorescence images and quantification of YP1/PI staining in MKN-45 cells. YP1⁺ cells (green) indicate apoptosis/necroptosis; PI⁺ cells (red) indicate necroptosis, pyroptosis, or ferroptosis. Scale bar = 50 μm. **P < 0.01 versus si-NC; ##P < 0.01 versus IFN-γ alone. C Western blot analysis of PANoptosis markers (p-MLKL, c-GSDME, c-caspase3) and HEATR1 in MKN-45 cells. D Bright field (BF) and HE staining of patient-derived organoids (PDOs) and tumor tissues with HEATR1 high and low expressions. E Immunofluorescence staining against HEATR1 of PDOs and tumor tissues. F Western blot analysis of PANoptosis markers in PDOs with high versus low HEATR1 expression following IFN-γ treatment. G Western blot analysis of PANoptosis markers in tumor tissues from the CD8⁺ T cell adoptive transfer sh-HEATR1 MFC model, with or without anti-IFN-γ antibody treatment. Data represent mean ± SD. N = 3 Meanwhile, the expression of PANoptosis markers was also upregulated in HEATR1 knockdown tumor tissues from 615 mice, as well as in low HEATR1-expressing PDOs and MKN-45 cells exposed to IFN-γ (Fig. 3D-F). Conversely, the expression of PANoptosis markers was downregulated in HEATR1 knockdown MFC cells exposed to anti-IFN-γ neutralized tumor supernatants from the sh-HEATR1 MFC s.c. group (Figure S3). Furthermore, increased PANoptosis was detected in tumor tissues from the CD8+ T cell adoptive transfer sh-HEATR1 MFC model, while the corresponding PANoptosis markers were significantly reduced in tumors treated with anti-IFN-γ antibody (Fig. 3G), further suggesting that the onset of PANoptosis in HEATR1 knockdown tumor cells is regulated by IFN-γ derived from CD8+ T cells. HEATR1 knockdown-induced PANoptosis depends on STAT1/IRF1 signaling Recent studies have identified IRF1 as an upstream regulator of PANoptosis (Sharma et al. 2023). The STAT1/IRF1 axis plays a crucial role in IFN-induced inflammatory cell death (Karki et al. 2021). IFN-γ treatment of HEATR1 knockdown MKN-45 cells promoted the protein expression of phosphorylated STAT1 and IRF1, concomitant with increased PANoptosis markers (Figure S4C), suggesting activation of the IFN-γ/STAT1/IRF1 signaling pathway. We further observed elevated expression of STAT1, p-STAT1, IRF1, and IFN-γ in subcutaneous syngeneic tumors from HEATR1 knockdown tumor-bearing 615 mice (Fig. 4A). Consistent with these in vivo findings, HEATR1 knockdown induced the expression of STAT1, p-STAT1, and IRF1 in IFN-γ-treated MKN-45 cells (Fig. 4B). IRF1 has been reported to contribute to the activation of ZBP1-, AIM2-, RIPK1-, and NLRP12-PANoptosomes and the induction of PANoptosis (Sharma et al. 2023). Accordingly, ZBP1, AIM2, RIPK1, and NLRP12 expressions were all upregulated in IFN-γ-treated HEATR1 knockdown MFC cells (Figure S4D), indirectly supporting the potential involvement of IRF1-mediated PANoptosis. Fig. 4HEATR1 knockdown-induced PANoptosis depends on STAT1/IRF1 signaling. A Western blot analysis of STAT1, p-STAT1 (Tyr701), IRF1, and IFN-γ expression in subcutaneous syngeneic tumor tissues from 615 mice bearing sh-NC or sh-HEATR1 MFC tumors. B Western blot analysis of STAT1, p-STAT1 (Tyr701), IRF1, and HEATR1 expression in MKN-45 cells with si-HEATR1 and/or IFN-γ treatment. C-D MKN-45 cells were transfected with si-IRF1 and/or si-HEATR1 and treated with IFN-γ. C YP1/PI staining and quantification of cell death. Scale bar = 50 μm. D Western blot analysis of PANoptosis markers (p-MLKL, c-GSDME, and c-caspase3). **P < 0.01, ***P < 0.001 vs. si-NC; ##P < 0.01 vs. IFN-γ + si-HEATR1. E CHX chase assay showing STAT1 and IRF1 protein stability in si-HEATR1-transfected MKN-45 cells for indicated time points. **P < 0.01 vs. si-NC at corresponding time point. F Western blot analysis of STAT1 expression in MKN-45 cells with or without si-HEATR1 transfection following MG132 treatment. G Co-immunoprecipitation analysis of STAT1 ubiquitination in MKN-45 cells with or without si-HEATR1 transfection. Cells were treated with MG132 and subjected to immunoprecipitation with anti-STAT1 antibody, followed by Western blot detection of ubiquitin (Ub). H Proteasome activity assay (including chymotrypsin-like, trypsin-like, and caspase-like activities) in MKN-45 cells transfected with si-NC or si-HEATR1. *P < 0.05 vs. si-NC. I Proteasome activity assay (including chymotrypsin-like, trypsin-like, and caspase-like activities) in MFC subcutaneous syngeneic tumors from 615 mice bearing sh-NC or sh-HEATR1 tumors. **P < 0.01 vs. sh-NC. J qRT-PCR analysis of IRF1 mRNA expression in subcutaneous syngeneic tumor tissues from 615 mice. **P < 0.01 vs. sh-NC. K qRT-PCR analysis of IRF1 mRNA expression in MKN-45 cells with HEATR1 knockdown and/or IFN-γ treatment. *P < 0.05 versus IFN-γ alone. L Western blot analysis of STAT1, p-STAT1 (Tyr701), and IRF1 expression in MKN-45 cells with HEATR1 knockdown treated with IFN-γ and/or fludarabine (STAT1 inhibitor). Data represent mean ± SD. N = 3 HEATR1 knockdown-induced PANoptosis depends on STAT1/IRF1 signaling. A Western blot analysis of STAT1, p-STAT1 (Tyr701), IRF1, and IFN-γ expression in subcutaneous syngeneic tumor tissues from 615 mice bearing sh-NC or sh-HEATR1 MFC tumors. B Western blot analysis of STAT1, p-STAT1 (Tyr701), IRF1, and HEATR1 expression in MKN-45 cells with si-HEATR1 and/or IFN-γ treatment. C-D MKN-45 cells were transfected with si-IRF1 and/or si-HEATR1 and treated with IFN-γ. C YP1/PI staining and quantification of cell death. Scale bar = 50 μm. D Western blot analysis of PANoptosis markers (p-MLKL, c-GSDME, and c-caspase3). **P < 0.01, ***P < 0.001 vs. si-NC; ##P < 0.01 vs. IFN-γ + si-HEATR1. E CHX chase assay showing STAT1 and IRF1 protein stability in si-HEATR1-transfected MKN-45 cells for indicated time points. **P < 0.01 vs. si-NC at corresponding time point. F Western blot analysis of STAT1 expression in MKN-45 cells with or without si-HEATR1 transfection following MG132 treatment. G Co-immunoprecipitation analysis of STAT1 ubiquitination in MKN-45 cells with or without si-HEATR1 transfection. Cells were treated with MG132 and subjected to immunoprecipitation with anti-STAT1 antibody, followed by Western blot detection of ubiquitin (Ub). H Proteasome activity assay (including chymotrypsin-like, trypsin-like, and caspase-like activities) in MKN-45 cells transfected with si-NC or si-HEATR1. *P < 0.05 vs. si-NC. I Proteasome activity assay (including chymotrypsin-like, trypsin-like, and caspase-like activities) in MFC subcutaneous syngeneic tumors from 615 mice bearing sh-NC or sh-HEATR1 tumors. **P < 0.01 vs. sh-NC. J qRT-PCR analysis of IRF1 mRNA expression in subcutaneous syngeneic tumor tissues from 615 mice. **P < 0.01 vs. sh-NC. K qRT-PCR analysis of IRF1 mRNA expression in MKN-45 cells with HEATR1 knockdown and/or IFN-γ treatment. *P < 0.05 versus IFN-γ alone. L Western blot analysis of STAT1, p-STAT1 (Tyr701), and IRF1 expression in MKN-45 cells with HEATR1 knockdown treated with IFN-γ and/or fludarabine (STAT1 inhibitor). Data represent mean ± SD. N = 3 To further clarify whether IRF1 is required for PANoptosis in HEATR1 knockdown cells, we generated MKN-45 and cells with knockdown of IRF1, HEATR1, or both. IRF1 knockdown reduced the percentages of YP1- and PI-positive cells in HEATR1-deficient cells under IFN-γ stimulation (Fig. 4C). The concomitant reduction in PANoptosis marker expression confirmed that IRF1 is required for HEATR1 knockdown-induced PANoptosis in GC cells (Fig. 4D). HEATR1 has been implicated in cytoplasmic proteasome activity (Yang et al. 2023). Cycloheximide (CHX) chase experiments revealed that HEATR1 knockdown significantly delayed STAT1 protein degradation in MKN-45 cells under both basal and IFN-γ-stimulated conditions (Fig. 4E, right panels). Notably, HEATR1 deficiency also moderately attenuated IRF1 degradation, particularly evident at the 2-hour time point in IFN-γ-treated cells (Fig. 4E, left panels), suggesting that HEATR1 may indirectly influence IRF1 stability through its primary regulatory effect on STAT1. These results indicate that HEATR1 regulates STAT1 protein degradation; under HEATR1-silenced conditions, the post-translational degradation pathway of STAT1 is constitutively restricted, independent of IFN-γ exposure. Consequently, cells with higher basal STAT1 levels exhibited enhanced responsiveness to IFN-γ-induced activation signals, leading to increased STAT1 phosphorylation. MG132 was used to inhibit proteasome activity in MKN-45 cells with or without HEATR1 knockdown. While MG132 increased STAT1 abundance in control MKN-45 cells, it failed to produce comparable effects in HEATR1 knockdown cells (Fig. 4F), suggesting that HEATR1 regulates STAT1 expression through modulation of proteasomal degradation. Furthermore, co-immunoprecipitation studies revealed that neither STAT1 nor IRF1 directly binds to HEATR1 (Figure S4E). Co-immunoprecipitation analysis showed that HEATR1 knockdown did not significantly change STAT1 ubiquitination levels (Fig. 4G), indicating that HEATR1 regulates STAT1 degradation independently of ubiquitination modification. STAT1 is highly susceptible to ubiquitination and rapid proteasomal degradation; accordingly, proteasome inhibition effectively stabilizes its protein levels (Forget et al. 2005, Kim and Maniatis 1996). We found that HEATR1 obviously affected proteasome activity (Fig. 4H-I). These findings indicate that HEATR1 regulates STAT1 degradation indirectly through modulation of proteasome activity rather than direct protein-protein interaction or ubiquitination. Additionally, HEATR1 knockdown potently increased IRF1 mRNA levels both in vivo and in vitro (Fig. 4J-K). Moreover, fludarabine, a specific STAT1 inhibitor, attenuated the upregulation of IRF1 induced by HEATR1 knockdown (Fig. 4L). To further validate our findings, we employed an additional GC cell line, HGC-27 cells. Similar to MKN-45 cells, HGC-27 cells with HEATR1 knockdown exhibited a more pronounced PANoptotic state upon IFN-γ stimulation, as evidenced by Western blotting of PANoptosis markers and YO-PRO-1/PI staining (Figure S3C-D). Additionally, p-STAT1/IRF1 signaling was markedly enhanced in these cells (Figure S4A). Notably, when IRF1 was knocked down, IFN-γ-induced apoptosis and necrosis in HEATR1-deficient HGC-27 cells were significantly attenuated (Figure S4B). Collectively, these data demonstrate that HEATR1 increases IRF1 transcription by regulating STAT1 activity, thereby influencing PANoptosis in response to IFN-γ stimulation. HEATR1 knockdown-mediated PANoptosis contributes to antigen priming of DCs to enhance CD8+ T cell expansion Maturation and activation of DCs are essential for their migration to the T-cell region of lymph nodes (Fang et al. 2014), whereas mature cytotoxic T cells exert their anti-tumor effects through IFN-γ secretion (Zhou et al. 2024). Therefore, DC maturation may be associated with increased IFN-γ secretion in tumors. In this study, we observed a higher proportion of mature DCs in tumor-draining lymph nodes (tdLNs) following HEATR1 knockdown (Figure S5A). In DC depletion models using 615 mice, the anti-tumor efficacy was attenuated, suggesting that the anti-tumor effect mediated by HEATR1 knockdown in immunocompetent mice is dependent on DCs (Figure S5B). Stimulation with supernatants from IFN-γ-stressed, HEATR1 knockdown MKN-45 cells induced DC maturation in vitro, as evidenced by upregulation of CD80 and CD86 (Figure S5C), and these pulsed DCs enhanced CD8+ T cell expansion (Figure S5D), indicating that supernatants from PANoptotic gastric tumor cells promote DC maturation. Efficient antigen transfer to DCs facilitates presentation to CD8+ T cells and elicits robust immune responses. PANoptosis drives effective tumor-specific immune responses by inducing the release of damage-associated molecular patterns (DAMPs)(Zheng et al. 2020). In the present study, HEATR1 knockdown significantly increased HMGB1 protein levels (a DAMP marker) in subcutaneous syngeneic tumors (Fig. 5A). In vitro, we observed enhanced release of HMGB1 and HSP70 from IFN-γ-treated MKN-45 cells following HEATR1 knockdown (Fig. 5B). Furthermore, blockade of DAMP receptor signaling using anti-TLR4 monoclonal antibody prior to stimulation with MKN-45 supernatants markedly reduced DC maturation, with a particularly pronounced decrease in the group stimulated with supernatants from IFN-γ-treated cells (Fig. 5C-D). We next investigated whether PANoptosis specifically affects the release of HMGB1 and HSP70. HEATR1 knockdown MKN-45 cells were treated with Z-VAD-FMK (apoptosis inhibitor), necrostatin-1 (necroptosis inhibitor), and Ac-DMPD (pyroptosis inhibitor) alone or in combination with IFN-γ. Notably, Z-VAD-FMK, necrostatin-1, and Ac-DMPD attenuated but did not completely reverse the increased HMGB1 and HSP70 release induced by HEATR1 knockdown in IFN-γ-treated MKN-45 cells (Fig. 5E). Consistently, DC maturation induced by supernatants from IFN-γ and HEATR1 knockdown MKN-45 cells, as well as CD8+ T cell expansion mediated by these mature DCs, were only partially inhibited by Z-VAD-FMK, necrostatin-1, and Ac-DMPD (Fig. 5F-G). In addition, concurrent inhibition with Z-VAD-FMK, necrostatin-1, and Ac-DMPD resulted in a more complete reversal of HMGB1 and HSP70 secretion. We performed these experiments in both MKN-45 and HGC-27 cell lines, and found that the HEATR1 knockdown in IFN-γ-treated cells reduced the concurrent inhibition of HMGB1 and HSP70 secretion (Figure S5E-F). These results demonstrate that gastric cancer cell PANoptosis enhances DC cross-presentation to CD8+ T cells through regulated DAMP release, thereby promoting the infiltration of IFN-γ-producing effector CD8+ T cells. Fig. 5HEATR1 knockdown-mediated PANoptosis enhances DC maturation and CD8⁺ T cell expansion through DAMP release. A Immunofluorescence staining and quantification of HMGB1 in subcutaneous syngeneic tumor tissues from 615 mice bearing sh-NC or sh-HEATR1 MFC tumors. Nuclei were counterstained with DAPI (blue). Scale bar = 20 μm. **P < 0.01 vs. sh-NC. B ELISA quantification of HMGB1 and HSP70 levels in supernatants from MKN-45 cells with HEATR1 knockdown and/or IFN-γ treatment. *P < 0.05, **P < 0.01 versus si-NC; ##P < 0.01 vs. IFN-γ alone. C-D DCs derived from human PBMCs were stimulated with supernatants from HEATR1 knockdown MKN-45 cells in the presence or absence of anti-TLR4 blocking antibody. C Flow cytometric analysis of mature DCs (HLA-DR⁺CD86⁺). D Flow cytometric analysis of CD8⁺ T cell proliferation (Ki67⁺CD8⁺) following co-culture with pulsed DCs. **P < 0.01 versus control; ##P < 0.01 vs. IFN-γ + si-HEATR1 without anti-TLR4. E ELISA quantification of HMGB1 and HSP70 levels in supernatants from siRNA-mediated HEATR1 knockdown MKN-45 cells treated with PANoptosis inhibitors (Z-VAD-FMK, necrostatin-1, or Ac-DMPD) and/or IFN-γ. **P < 0.01 vs. vehicle control. F Flow cytometric analysis of mature DCs (HLA-DR⁺CD86⁺) stimulated with supernatants from MKN-45 cells treated with PANoptosis inhibitors and/or IFN-γ. **P < 0.01 vs. vehicle control. G Flow cytometric analysis of CD8⁺ T cell proliferation (Ki67⁺CD8⁺) following co-culture with DCs pulsed with supernatants from MKN-45 cells treated with PANoptosis inhibitors and/or IFN-γ. **P < 0.01 vs. vehicle control. Data represent mean ± SD. N = 3 HEATR1 knockdown-mediated PANoptosis enhances DC maturation and CD8⁺ T cell expansion through DAMP release. A Immunofluorescence staining and quantification of HMGB1 in subcutaneous syngeneic tumor tissues from 615 mice bearing sh-NC or sh-HEATR1 MFC tumors. Nuclei were counterstained with DAPI (blue). Scale bar = 20 μm. **P < 0.01 vs. sh-NC. B ELISA quantification of HMGB1 and HSP70 levels in supernatants from MKN-45 cells with HEATR1 knockdown and/or IFN-γ treatment. *P < 0.05, **P < 0.01 versus si-NC; ##P < 0.01 vs. IFN-γ alone. C-D DCs derived from human PBMCs were stimulated with supernatants from HEATR1 knockdown MKN-45 cells in the presence or absence of anti-TLR4 blocking antibody. C Flow cytometric analysis of mature DCs (HLA-DR⁺CD86⁺). D Flow cytometric analysis of CD8⁺ T cell proliferation (Ki67⁺CD8⁺) following co-culture with pulsed DCs. **P < 0.01 versus control; ##P < 0.01 vs. IFN-γ + si-HEATR1 without anti-TLR4. E ELISA quantification of HMGB1 and HSP70 levels in supernatants from siRNA-mediated HEATR1 knockdown MKN-45 cells treated with PANoptosis inhibitors (Z-VAD-FMK, necrostatin-1, or Ac-DMPD) and/or IFN-γ. **P < 0.01 vs. vehicle control. F Flow cytometric analysis of mature DCs (HLA-DR⁺CD86⁺) stimulated with supernatants from MKN-45 cells treated with PANoptosis inhibitors and/or IFN-γ. **P < 0.01 vs. vehicle control. G Flow cytometric analysis of CD8⁺ T cell proliferation (Ki67⁺CD8⁺) following co-culture with DCs pulsed with supernatants from MKN-45 cells treated with PANoptosis inhibitors and/or IFN-γ. **P < 0.01 vs. vehicle control. Data represent mean ± SD. N = 3 HEATR1 knockdown PDOs were prone to PANoptosis and enhanced DC-primed CD8+ T cell expansion Constrained by the administration of allogeneic immune cells targeting MKN-45, it was difficult to evaluate the specific anti-tumor efficacy of pulsed DC expanded in vitro. However, the autologous PDO-immune cell co-culture system allowed the evaluation of the cytotoxic ability of CD8+ T cells activated by autologous DC primed. The workflow diagram is shown in Fig. 6A, four nodes at IFN-γ stressed PDO (Fig. 6B), PDO supernatant pulsed dendritic cell (Fig. 6C), CD8+ T activation efficiency (Fig. 6D), and PDO apoptotic assay (Fig. 6E) were used to evaluate the feasibility of this system (marked by red boxes in Fig. 6A). Fig. 6HEATR1 knockdown PDOs were prone to PANoptosis and enhanced DC-primed CD8+ T cell expansion. A PDOs and PMBC-derived CD8+ T cells and immature DCs were obtained from the same patient. After pulsing with PDO supernatants, mature DCs were cocultured with CD8+ T cells. B LV-mediated HEATR1 knockdown PDOs were cultured and treated with IFN-γ. B-a The surface area of PDOs was measured and cell death was assessed by YP1/PI staining (scale bar = 500 μm). *P < 0.05, **P < 0.01. B-b ELISA detection of HMGB1 and HSP70 levels in the supernatant of PDOs after IFN-γ treatment. *P < 0.05, **P < 0.01. B-c Western blot analysis of MLKL, p-MLKL, GSDME, c-GSDME, caspase3, c-caspase3, STAT1, p-STAT1, IRF1, and HEATR1 expression. C Flow cytometric analysis of the percentage of CD80+CD86+ cells. **P < 0.01. D-a Flow cytometric analysis of the percentage of Ki67+CD8+ cells. *P < 0.05, **P < 0.01. D-b ELISA detection of IFN-γ levels. Compared with group 1, **P < 0.01; compared with group 3, ##P < 0.01. E Flow cytometric analysis of early (Annexin V+/PI−) and late (Annexin V+/PI+) apoptosis of tumor cells in the co-culture system. Compared with group 1, *P < 0.05, **P < 0.01; compared with group 3, ##P < 0.01. Data represent mean ± SD. N = 3 HEATR1 knockdown PDOs were prone to PANoptosis and enhanced DC-primed CD8+ T cell expansion. A PDOs and PMBC-derived CD8+ T cells and immature DCs were obtained from the same patient. After pulsing with PDO supernatants, mature DCs were cocultured with CD8+ T cells. B LV-mediated HEATR1 knockdown PDOs were cultured and treated with IFN-γ. B-a The surface area of PDOs was measured and cell death was assessed by YP1/PI staining (scale bar = 500 μm). *P < 0.05, **P < 0.01. B-b ELISA detection of HMGB1 and HSP70 levels in the supernatant of PDOs after IFN-γ treatment. *P < 0.05, **P < 0.01. B-c Western blot analysis of MLKL, p-MLKL, GSDME, c-GSDME, caspase3, c-caspase3, STAT1, p-STAT1, IRF1, and HEATR1 expression. C Flow cytometric analysis of the percentage of CD80+CD86+ cells. **P < 0.01. D-a Flow cytometric analysis of the percentage of Ki67+CD8+ cells. *P < 0.05, **P < 0.01. D-b ELISA detection of IFN-γ levels. Compared with group 1, **P < 0.01; compared with group 3, ##P < 0.01. E Flow cytometric analysis of early (Annexin V+/PI−) and late (Annexin V+/PI+) apoptosis of tumor cells in the co-culture system. Compared with group 1, *P < 0.05, **P < 0.01; compared with group 3, ##P < 0.01. Data represent mean ± SD. N = 3 To further confirm the effect of HEATR1 expression on organoid function in GC patients with the same genotype, we constructed a HEATR1 silent stable strain (LV-sh-HEATR1) for HEATR1 knockdown in PDOs. The HEATR1 knockdown PDOs were cultured and treated with IFN-γ. HEATR1 knockdown reduced the average size of PDOs (Fig. 6B-a). YP1/PI staining showed that HEATR1 knockdown sensitized PDOs to cell death and reduced surface area (Fig. 6B-a). HMGB1 and HSP70 release from PDOs was also increased (Fig. 6B-b). Meanwhile, the change trend of PANoptosis markers in PDOs was found to be consistent with the results in MKN-45 cells, as well as STAT1/IRF1 signaling (Fig. 6B-c). The efficiency of DC maturation pulsed by PDO supernatant from the above group was determined. The results showed the most significant proportion of CD80+CD86+ DCs (Fig. 6C) under the stimulation of supernatants, and their superior antigen presenting ability further contributed to the promotion of CD8+ T-cell expansion (Fig. 6D-a), as well as the generation of IFN-γ (Fig. 6D-b). HEATR1 knockdown PDOs showed increased susceptibility to the cytotoxic effects exerted by autologous cytotoxic T lymphocytes (CTLs) of the same origin, as indicated by a significant increase in early and late apoptosis of cancer cells, indicating the occurrence of PANoptosis (Fig. 6E). However, when IFN-γ neutralizing is added, PANoptosis is significantly reduced (Fig. 6E), suggesting that CTLs may initiate PANoptosis of PDOs by secreting IFN-γ, which further reflects the HEATR1 mechanism mediating IRF1-related PANoptosis. The above results indicate that in the tumor microenvironment, PANoptosis of GC cells after HEATR1 knockdown promotes the expansion of CD8+ T cells and further expands the killing effect of CD8+ T cells, thus forming positive feedback to enhance the killing ability of the immune microenvironment on GC cells. HEATR1 knockdown enhanced the anti-tumor effect of anti-PD1 in vivo ICI is an important treatment for GC, and studies have reported that CTL infiltration is beneficial for anti-PD1 treatment (He et al. 2017). To further evaluate whether HEATR1 knockdown helps to enhance the therapeutic efficacy of anti-PD1, HEATR1 knockdown MFC cells were subcutaneously inoculated into 615 mice. HEATR1 knockdown significantly enhanced anti-PD1-induced tumor growth inhibition (Fig. 7A). CD8+ cells were mainly located in the subcutaneous syngeneic tumors (Fig. 7B). HEATR1 knockdown synergistically increased the percentage of CD3+CD8+ cells (activated cytotoxic T cells) in the subcutaneous syngeneic tumors with anti-PD1 treatment (Fig. 7C). Accordingly, the combination of HEATR1 knockdown and anti-PD1 treatment resulted in a significant increase in IFN-γ expression of CD3+CD8+ cells (Fig. 7C-D). It was also found that the number of mature DCs in tdLN and tumor PANoptosis were significant (Fig. 7E-F). Taken together, these results indicated that HEATR1 knockdown increased the infiltration of CD8+ effector T cells and enhanced the anti-tumor effect of anti-PD1. Fig. 7HEATR1 knockdown enhanced the anti-tumor effect of anti-PD1 in vivo. MFC cells were transfected with sh-HEATR1 and negative control. 615 mice were subcutaneously inoculated with HEATR1 knockdown MFC cells, and tumor-bearing mice received αPD-1 antibody intraperitoneally. 615 mice were grouped into sh-NC, sh-HEATR1, sh-NC + αPD-1, and sh-HEATR1 + αPD-1 (N = 5 per group). A Tumor volumes were measured. Compared with sh-NC, *P < 0.05, **P < 0.01; compared with sh-NC + αPD-1, #P < 0.05. Scale Bar = 10 mm. B Immunofluorescence analysis of CD8 in tumor tissues. The nucleus was stained with DAPI (blue) (scale bar = 20 μm). C Flow cytometric analysis of the ratio of CD3+CD8+ cells in the single cell suspension from tumor tissues and further analysis of the expression of IFN-γ on CD3+CD8+ cells. **P < 0.01. D IFN-γ levels in tumors. **P < 0.01. E Flow cytometric analysis of the ratio of CD80+CD86+/CD11c+ cells. **P < 0.01. F Western blot analysis of MLKL, p-MLKL, GSDME, c-GSDME, caspase3 and c-caspase3, IFN-γ, STAT1, p-STAT1, IRF1, and HEATR1 expression. Data represent mean ± SD. N = 3 HEATR1 knockdown enhanced the anti-tumor effect of anti-PD1 in vivo. MFC cells were transfected with sh-HEATR1 and negative control. 615 mice were subcutaneously inoculated with HEATR1 knockdown MFC cells, and tumor-bearing mice received αPD-1 antibody intraperitoneally. 615 mice were grouped into sh-NC, sh-HEATR1, sh-NC + αPD-1, and sh-HEATR1 + αPD-1 (N = 5 per group). A Tumor volumes were measured. Compared with sh-NC, *P < 0.05, **P < 0.01; compared with sh-NC + αPD-1, #P < 0.05. Scale Bar = 10 mm. B Immunofluorescence analysis of CD8 in tumor tissues. The nucleus was stained with DAPI (blue) (scale bar = 20 μm). C Flow cytometric analysis of the ratio of CD3+CD8+ cells in the single cell suspension from tumor tissues and further analysis of the expression of IFN-γ on CD3+CD8+ cells. **P < 0.01. D IFN-γ levels in tumors. **P < 0.01. E Flow cytometric analysis of the ratio of CD80+CD86+/CD11c+ cells. **P < 0.01. F Western blot analysis of MLKL, p-MLKL, GSDME, c-GSDME, caspase3 and c-caspase3, IFN-γ, STAT1, p-STAT1, IRF1, and HEATR1 expression. Data represent mean ± SD. N = 3 Discussion GC is a common malignant tumor of the digestive tract with a high number of new cases and deaths worldwide. With the emergence of chemotherapy resistance, the prescription of conventional chemotherapy has limited efficacy for patients with advanced GC (Zhan et al. 2022). The development of ICIs addresses the limitations of conventional chemotherapy. To date, many cancers, such as lung cancer, melanoma, breast cancer, and kidney cancer, have shown good efficacy after immunotherapy with PD-1/PD-L1 blockers (Liu et al. 2020). Immunotherapy with ICIs has gradually become one of the important therapeutic methods in the field of GC. ICIs mainly block the immune checkpoint proteins or ligands on the surface of T cells or tumor cells, block tumor escape, and reactivate the ability of the host immune system to kill tumor cells, thereby inhibiting tumor progression (He et al. 2024). HEATR1 is highly expressed in GC tissues, and HEATR1 knockdown can significantly inhibit cell proliferation and colony formation and promote cell apoptosis (Zhao et al. 2020), suggesting that HEATR1 may be a target for the treatment of GC. In this study, we found that HEATR1 was associated with the development of GC and CD8+ T infiltration through bioinformatics analysis. In addition, CD8+ T cell infiltration was relatively low in the clinical samples of GC tissues in the HEATR1 high expression group. Further in vivo experiments showed that HEATR1 knockdown suppressed tumor growth and increased CD8+ T cell infiltration in 615 mice (Fig. 8). Fig. 8The knockdown of HEATR1 resulted in the induction of PANoptosis in GC cells via the STAT1/IRF1 pathway, which in turn facilitated the infiltration of CD8+ T cells and enhanced the killing ability of the immune microenvironment The knockdown of HEATR1 resulted in the induction of PANoptosis in GC cells via the STAT1/IRF1 pathway, which in turn facilitated the infiltration of CD8+ T cells and enhanced the killing ability of the immune microenvironment PANoptosis is a newly defined and strongly immune-related form of programmed cell death, which involves the activation of apoptosis, necroptosis and pyroptosis. PANoptosis plays an important role in a variety of immune and inflammatory diseases due to its strong immune inflammation (Li et al. 2019). In addition to its association with immunoinflammatory diseases, PANoptosis can also affect the occurrence, development and treatment of cancer(Karki et al. 2021, Bae et al. 2024, Gao et al. 2024). It has been found that PANoptosis promotes the maturation of DCs and presents antigens to T cells, while the T cells recruited to tumor tissue effectively play an immune killing role (Zhou et al. 2024). T cells are the most abundant and characteristic cells in the tumor microenvironment. CD8+ T cells can exert anti-tumor effects by targeting tumor antigens, and high infiltration levels of CD8+ T cells are associated with a better prognosis for cancer (Vesely et al. 2011, Galon et al. 2006). Here, GC cells with HEATR1 knockdown and IFN-γ treatment in vitro showed obvious PANoptosis, increased expressions of DAMPs markers HMGB1 and HSP70, promoted DCs maturation and enhanced CD8+ T cells expansion ability through regulating the release of DAMPs. Studies have confirmed that PANoptosis is involved in tumor progression. For example, IRF1 can delay the development of colorectal cancer by promoting PANoptosis pathway (Karki et al. 2020). IRF is closely related to the development of GC, IRF1 can improve the chemosensitivity of GC cells to 5-fluorouracil by inducing apoptosis of cancer cells (Gao et al. 2012), and IRF2 can inhibit the proliferation of GC cells by regulating the Wnt/β-catenin signaling pathway (Chen et al. 2022). Notably, IFN-STAT1 is upstream of IRF1 (Liang et al. 2020), and the STAT1/IRF1 axis plays an essential role in IFN-induced inflammatory cell death (Karki et al. 2021). The STAT protein family consists of seven key proteins, namely STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b and STAT6. STAT1 was first discovered the STAT family members. Studies have shown that STAT1 can inhibit tumor growth and participate in the progression and metastasis of various tumors, including GC (Li et al. 2023, Huo et al. 2023). We found that knockdown of HEATR1 mainly regulated the proteasomal degradation of STAT1 but not IRF1 in GC cells. Further experiments confirmed that HEATR1 increases the transcription of IRF1 by regulating the activity of STAT1 to affect the degree of PANoptosis induced by IFN-γ. Notably, HEATR1 knockdown alone caused a slight early apoptosis of GC cells, but had no significant effect on the total number of cells. Further investigation showed that HEATR1 knockdown alone could not effectively induce PANoptosis, and the occurrence of PANoptosis could only be enhanced by co-treatment with IFN-γ. This may be because HEATR1 knockdown mainly affects the protein expression of STAT1, but its ability to promote the expression of phosphorylated STAT1 is limited. Under the stimulation of IFN-γ, GC cells spontaneously promote the phosphorylation of STAT1 to initiate the downstream IRF1 signaling pathway, and the synchronous HEATR1 knockdown led to higher STAT1 expression, resulting in an increase in the total amount of phosphorylated STAT1, thus promoting the occurrence of IRF1-mediated PANoptosis. This is the first to explore the molecular mechanism of PANoptosis occurred in GC cells, and the discovery of the mechanism of HEATR1 mediating PANoptosis of GC cells is helpful to provide new research ideas for ICIs and promote the therapeutic efficiency of ICIs in GC. In this study, we presented both direct contact co-culture (Fig. 2A-B, and G) and Transwell systems (Fig. 2C-F) for TIL-derived CD8+ T cells with MFC cells. In the direct contact co-culture system, HEATR1-low MFC cells exhibited increased susceptibility to CD8+ T cell-mediated cytotoxicity (Fig. 2A). Notably, at identical effector-to-target (E: T) ratios, no significant difference in the proportion of CD107a+ CD8+ T cells was observed between the two groups (Fig. 2B). To determine whether residual killing activity originated from non-contact mechanisms, we employed a Transwell system (Fig. 2C-F), in which CD8+ T cells and MFC cells were co-cultured in separate chambers. The results indicated that CD8+ T cell-derived IFN-γ likely served as the primary driver of the additional cytotoxicity observed in the HEATR1-knockdown group under these conditions (Fig. 2D-F). Accordingly, the residual killing in the sh-HEATR1 group may be attributed to paracrine signaling mediated by CD8+ T cell-derived IFN-γ. Admittedly, compared to the Transwell system, direct contact co-culture elicited more potent CD8+ T cell cytotoxicity, particularly at high E: T ratios, where the difference in killing efficacy between the two groups gradually diminished. However, such high E: T ratios (CD8+ T cells: tumor cells) are unattainable in vivo within tumor tissue microenvironments. Therefore, knocking down tumor cell HEATR1 to enhance sensitivity to tumor-reactive T cells remains a promising strategy warranting further investigation. PDOs are a kind of stereoscopic model that is highly similar to the characteristics of patients’ tumors, which is established by three-dimensional cell culture system in vitro (Drost and Clevers 2018). PDOs are highly consistent with patients’ tumor histopathological characteristics, molecular characteristics, drug sensitivity, genetic stability, etc., and can be cultured in vitro for a long time and passed stably, which is a very effective preclinical model (Veninga and Voest 2021). To further confirm the regulation of HEATR1 on PANoptosis of GC cells, PDOs with high and relatively low HEATR1 expression were cultured, and it was found that PANoptosis in the low HEATR1 expression group PDOs was stronger and the HMGB1 and HSP70 contents were higher. In addition, the stabling HEATR1 silencing PDOs enhanced the expansion and killing effect of CD8+ T cell. The use of the PDO models makes our findings more closely related to the actual application effect in human. In vitro, HEATR1 knockdown alone induces only a minor degree of early apoptosis in GC cells, which is consistent with previous findings (Zhao et al. 2020). However, HEATR1-silenced MFC cells exhibit markedly superior tumor suppressive capacity in immunocompetent mice. While this discrepancy may partially reflect heterogeneity in tumor cell lines used by different research groups, it more strongly suggests that the immune microenvironment serves as the primary regulatory mechanism constraining the growth of HEATR1-silenced MFC tumors. The role of tumor-intrinsic PANoptosis in modulating anti-tumor immune microenvironments has been well established (Zhou et al. 2024). Further studies reveal that HEATR1 knockdown alone is insufficient to effectively trigger PANoptosis. Instead, the induction of PANoptosis is significantly enhanced only when combined with IFN-γ treatment. This phenomenon may be attributed to the fact that HEATR1 knockdown primarily affects the expression levels of STAT1 protein, but its capacity to promote the phosphorylation of STAT1 is relatively limited. Upon stimulation with IFN-γ, GC cells inherently facilitate the phosphorylation of STAT1, thereby activating the downstream IRF1 signaling pathway. Concurrent HEATR1 knockdown results in elevated STAT1 expression, which in turn increases the total amount of phosphorylated STAT1. This ultimately enhances the occurrence of IRF1-mediated PANoptosis. There are still limitations to this study. Four PANoptosome complexes have been molecularly characterized, including Z-DNA binding protein 1 (ZBP1) (Kuriakose et al. 2016), absent in melanoma-2 (AIM2) (Lee et al. 2021), receptor-interacting protein kinase 1 (RIPK1) (Malireddi et al. 2020), and nucleotide binding oligomerization domain like receptor protein 12 (NLRP12) (Sundaram et al. 2023). IRF1 was found to help activate ZBP1-, AIM2-, RIPK1-, and NLRP12-PANoptosome and induce PANoptosis (Sharma et al. 2023). In the future, it is necessary to further investigate whether HEATR1/STAT1/IRF1 regulates PANptosome in PANoptosis. In addition, the mechanism by which GC cells affect the maturation of DCs and their ability to present antigen to CD8+ T cells after PANoptosis is not thoroughly investigated in this paper. Female mice were prioritized for our experiments due to their docile temperament and lower aggression. Additionally, several published studies (Jeong et al. 2025, Liu et al. 2017) have also employed female mice for GC transplantation models. Although the use of female mice facilitated experimental convenience, and GC pathogenesis is not fully correlated with sex hormone secretion, relying exclusively on female mice does not fully reflect the clinical scenario. In conclusion, this study was the first to investigate the mechanism of PANoptosis in coordination with anti-PD1 immunotherapy in GC. We found that HEATR1 knockdown induced PANoptosis of GC cells through STAT1/IRF1, and released DAMP markers enhanced DCs priming to CD8+ T cells, promoted CD8+ T cell infiltration and tumor killing effect, and finally enhanced the effect of anti-PD1 immunotherapy, providing a new opportunity for targeted treatment of GC. Supplementary Information Supplementary Material 1. Supplementary Material 1.